Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
First Affiliated Hospital of Zhejiang University
Dana-Farber Cancer Institute
AvenCell Therapeutics, Inc.
City of Hope Medical Center
Fate Therapeutics
Center for International Blood and Marrow Transplant Research
Incyte Corporation
Allogene Therapeutics
Ossium Health, Inc.
Ossium Health, Inc.
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Center for International Blood and Marrow Transplant Research
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
University of Arizona
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Stanford University
University of Pennsylvania
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Actinium Pharmaceuticals
Anhui Provincial Hospital
Cancer Trials Ireland
Masonic Cancer Center, University of Minnesota
University of Pennsylvania
City of Hope Medical Center
Dana-Farber Cancer Institute
Thomas Jefferson University
University College, London
Affiliated Hospital of Nantong University
Vastra Gotaland Region
Universitätsklinikum Hamburg-Eppendorf
Celgene
City of Hope Medical Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
National Institutes of Health Clinical Center (CC)